Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
About this trial
This is an interventional treatment trial for Fallopian Tube Cancer focused on measuring recurrent ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cavity cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer Measurable disease by physical exam, radiography, peritoneoscopy, or laparoscopy No more than 4 weeks since prior peritoneoscopy No brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 4 months Hematopoietic: Absolute neutrophil count at least 1,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 9.0 g/dL AND/OR Hematocrit at least 27% Hepatic: SGOT/SGPT no greater than 3 times upper limit of normal Bilirubin normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 50 mL/min Cardiovascular: No history of symptomatic cardiac dysrhythmias requiring medication At least 6 months since prior myocardial infarction No unstable or newly diagnosed angina Pulmonary: No obstructive lung disease requiring oxygen therapy Other: Not pregnant or nursing HIV negative Must be able to take oral medication No concurrent medical condition (e.g., impending bowel obstruction) No grade 2 or greater residual peripheral neuropathy No active infection No other prior or concurrent invasive malignancy within the past 5 years No history of acute visual loss other than that associated with retinal detachment PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior cytokine therapy No concurrent cytokine therapy to maintain WBC count Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin, or mitomycin) No other concurrent chemotherapy Endocrine therapy: At least 4 weeks since prior hormonal therapy No concurrent corticosteroids at doses greater than physiological replacement doses No concurrent hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics Other: No more than 3 prior treatment regimens At least 1 week since prior systemic antibiotics for infection No chronic antifungal treatment with antimycotic imidazoles No concurrent alternative therapies
Sites / Locations
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support